Theories of stem cell aging
Single-celled organisms and simple multicellular animals have lifespans commensurate with their cellular longevity. The evolution of highly specialized organ systems in complex organisms enabled organismal longevity that greatly exceeded the lifespan of almost all of its composite cells. This strategy was dependent on a source of cells to replace those lost by attrition during a lifetime of wear and tear. It is now known that stem cells located throughout the body in multiple organs serve this purpose and have lifespans that may equal or exceed those of the organism (Harrison, 1973) . However, because of the long life of stem cells and their potentially long replicative histories, they are subject to damage from several intracellular and extracellular sources. For example, the long-term exposure to reactive oxygen species (ROS) largely generated as a by-product of cellular metabolism is known to have deleterious effects on numerous cellular macromolecules, including proteins, nucleic acids and lipids. Although damages to each of these classes of molecules are individually important, and may be synergistic collectively, we wish to limit our discussion here to the nucleic acids and proteins that make up chromatin. A second major cause of damage may owe to the repetitive rounds of replication stem cells undergo during a lifetime. DNA replication results in numerous copy errors, the correction of which cells have evolved elaborate proofreading and editing mechanisms. Since these mechanisms' may be eroded with time (for example, as a result of oxidative damage), genetic damage may result and accumulate.
One strategy for stem cell populations to obviate the risk of damage from long replicative histories is through clonal succession, wherein the vast majority of the population is homeostatically maintained in a quiescent state, and one or at most several stem cells are actively simultaneously supplying differentiated cells (Kay, 1965) . In this way stem cells would replicate only as they assume the role of an active clone, and since they would continue to supply differentiated progeny through replication and differentiation until the clone was extinguished, they would not rejoin the pool of quiescent stem cells. Thus, the strategy of clonal succession supposes that the stem cell population would decrease in size with age as the number of used and extinguished clones grows. Crises during a lifetime requiring increased generation of differentiated cells would accelerate the rate of succession. To compensate for loss, one could postulate that a sufficiently large stem cell population could provide a buffer to not only meet the needs of homeostasis but also meet the needs of the crises as well.
Data obtained in experiments in which the thymidine analog bromodeoxyuridine (BrdU) was administered continuously to mice cast doubt on successive activation of stem cell clones, at least in blood cell formation. In these experiments, after as little as one month, more than half of the hematopoietic stem cells had incorporated BrdU, indicating that they had undergone at least one replication during that period; the population was nearly completely labeled in two months (Pietrzyk et al., 1985; Bradford et al., 1997; Cheshier et al., 1999) . All stem cells apparently replicate on a regular and frequent basis, thus dispelling one of the tenets of the clonal succession theory. However, the BrdU experiments do not address the issue of whether or not stem cells follow a pattern of sequential usage, but studies in vivo in mouse chimeras show that many, if not all, of hematopoietic stem cells simultaneously contribute to blood formation (Harrison et al., 1987) .
Evidence supporting aging of stem cells
In the analogy used to introduce this section, it might be argued that single-celled organisms, rather than having a limited longevity, live forever because they reproduce by fission, and daughter cells of the next generation are composed of the cellular components of the previous generation. In mammals, stem cells of the germ line are the only cells that maintain the link through organismal generations, and since sexual reproduction has evolved, two lineages of germ cells are responsible for the composition of each individual. Thus, the entire human race can be traced back to one ancestral couple. In an alternative model to clonal succession, a characteristic of adult stem cells that sets them apart from other somatic cells is their ability to replicate in the strictest sense: to generate at least one daughter cell that has equivalent developmental potential, a phenomenon known as self-renewal. It is this property, unnecessary in clonal succession, that has been hypothesized to ensure an unlimited supply of stem cells, irrespective of demands put on the system by aging or stress caused by injury or disease. In an experimental test that in some ways parallels the intergenerational span of germ line stem cells, hematopoietic stem cells have been serially transplanted through a succession of lethally irradiated hosts, and the originally engrafted stem cells must repopulate the hematopoietic systems of a series of 'generations'. Unlike germ line stem cells, adult stem cells such as those of the hematopoietic system are incapable of sustaining an indefinite line of generations (Siminovitch et al., 1964) . Rather, after no more than four or five generations, they are no longer able to sustain a myeloablated recipient. Although stem cell transplantation may not accurately reflect organization and usage of the stem cell population in unmanipulated animals or humans, it is the measure of stem cell function most consistent with the natural role of stem cells in vivo. The limited 'lifespan' of hematopoietic stem cells during serial transplantation, at least within the context of the experimental model, suggests that stem cells age. Correlates of cellular aging such as telomere shortening have been shown to accompany the decline in stem cell function in both serial transplantation and natural aging (Vaziri et al., 1994; Allsopp et al., 2001) . In contrast, the telomere lengths of embryonic stem cells and germ line stem cells do not change with serial passage in vitro and age, respectively (Counter, 1996; Liu et al., 2000) . Abundant expression of telomerase in embryonic, germ line and hematopoietic stem cells may account for at least part of the resistance to telomere erosion, but in hematopoietic stem cells either telomerase expression is not sufficient quantitatively or other mechanisms contribute to their aging (Allsopp et al., 2003) .
Stem cell renewal and aging
Within the last few years, several regulators of selfrenewal in the hematopoietic stem cell population have been identified: two Hox gene products, HOXB4 and HOXA9 (Sauvageau et al., 1995; Antonchuk et al., 2002; Thorsteinsdottir et al., 2002) and, more recently, PBX1 (Krosl et al., 2003) and the product of the Bmi-1 gene (Lessard and Sauvageau, 2003; Park et al., 2003) . Overexpression of these genes in hematopoietic stem cells, through transduction via viral vectors (HOXB4 and HOXA9), results in stem cells capable of enhanced renewal and, at least under some conditions, no evidence of tumorigenic transformation. If stem cell renewal limits normal functioning of adult tissues, which in turn limits organismal longevity, these models provide a test of the potential role of stem cells in aging and longevity. Enhanced stem cell renewal may prolong homeostatic tissue renewal with age and provide a buffer against replicative stresses that may occur. Although the studies to date have principally focused on the hematopoietic stem cell system, it is conceivable and perhaps likely that the Hox genes B4 and A9, and Bmi-1 affect the renewal of other adult stem cell populations as well. Therefore, a simple and straightforward test of this hypothesis may be to determine the effect of enhanced stem cell selfrenewal on tissue replenishment during aging and on organismal longevity.
Impact of aging stem cells on health
Human aging is accompanied by what on the surface seem to be subtle changes in hematopoiesis, including decreased marrow cellularity, anemia, and blunted immune responses (Lipschitz et al., 1981) . However, far less subtle age-related changes in blood formation become apparent in response to hematopoietic stress. Response may not only be slowed, but recovery may be incomplete even after long periods of time (Botnick et al., 1982; Marley et al., 1999; Kim et al., 2003) . For example, hematopoietic reserves are depleted during aging and account for significant morbidity and mortality in patients undergoing myeloablative cancer therapies. During homeostatic blood formation in the elderly, there is growing awareness that what have been regarded as subtle change only appears so in the context of normal values of young populations. Specifications of a significant proportion of the human population is anemic for reasons not easily explained by comorbidity factors such as iron or folate deficiencies (Balducci, 2003; Ershler, 2003; Rothstein, 2003) . Unexplained anemias account for nearly half of those seen in older patients, and the older the population, the greater the number of unexplained anemias becomes (Penninx et al., 2003;  The importance of stem cells in aging and leukemia development D R Bell and G Van Zant Cesari et al., 2004) . Although the severity of the anemia is modest and in most cases goes untreated, its symptoms in the elderly are out of proportion to the decline in hemoglobin. There may be multiple causes for the amplified effects of anemia in the elderly and for anemia itself. With respect to the latter, it may reflect a dysregulated red cell production in the bone marrow. Since stem cells are ultimately responsible for erythropoiesis, an important but unresolved question is the possibility that anemia in the elderly is, in many cases, a reflection of 'smoldering' myelodysplasia. This possibility brings us back to the point first made in this review; namely, that age-related accumulation in chromatin damage, especially in stem cells that are capable of passing such defects on to abundant progeny, may account for the dramatic increase in cancer seen after the age of 50.
Stem cells and cancer
The importance of stem cells in acute myelogenous leukemia (AML)
The unique ability of a stem cell to self-renew, differentiate into multiple lineages, and extensively proliferate underlies the crucial role of these cells in human development and homeostasis. In fact, most major organ systems of the body have been shown to contain and rely upon a pool of stem cells specific to that organ system, including the hematopoietic, central nervous, and hepatic systems (McKay, 1997; Clarke et al., 2000; Vicario-Abejon et al., 2000; Weissman, 2000; Hawke and Garry, 2001; Toma et al., 2001; Vessey and de la Hall, 2001) . The hematopoietic stem cell, or HSC, has been isolated and studied in detail in both man and mouse, and these cells are already widely used in clinical treatments as the critical component of bonemarrow transplantation therapies.
Cancers of the hematopoietic system, or leukemias, have been shown to originate from and be sustained by cancer stem cells. Leukemias provide the most convincing data that normal stem cells can become cancer stem cells through the acquisition of mutations, and it is this leukemic stem cell (LSC) that is responsible for the disease (Reya et al., 2001) . Studies of human AML have begun to define the genetic alterations and chromosome translocations associated with the various subtypes of the disease (Dash and Gilliland, 2001) . AML is a very heterogeneous disease clinically and includes many subtypes (M0-M7) as defined by the French-American-British (FAB) classification system (Mirro, 1992) . Despite this heterogeneity, the leukemias are quite similar at the level of the stem cell and also share many of the same immunophenotypic markers as normal HSCs (Lapidot et al., 1994; Bonnet and Dick, 1997) . With the advent of improved methods of detection and isolation of stem cells (such as fluorescence activated cell sorting, or FACS), it is now possible to analyze the functional and molecular characteristics of both normal HSCs and LSCs. Recent reports formally have described the existence of LSCs in AML and strongly suggest that these LSCs give rise to the disease (Jordan, 2002) . Specifically, when CD34 þ /CD38À cells, previously defined as containing the stem cell population of normal bone marrow (BM), were isolated from the BM of patients with AML and transplanted into the nonobese diabetic/severe combined immunodeficient (NOD/ SCID) mouse, leukemic disease was evident and transferable (Bonnet and Dick, 1997) . This indicates that, just like the normal HSC, the LSC also displays the cell surface marker phenotype of CD34 þ /CD38À. Other evidence supporting the stem cell origin of AML comes from studies on the various subtypes of the disease. As mentioned previously, AML subtype classification is based upon the morphologies and genetic abnormalities of the leukemic cells (FAB subtypes) (Brendel and Neubauer, 2000) . Interestingly, the AML subtypes M0, M1, M2, M4, and M5 all contain LSCs with similar immunophenotypes, even though each of these subtypes of leukemia displays a very different clinical disease (Guzman and Jordan, 2004) . While the phenotypically identical LSCs (CD34 þ /CD38À) from each of the AML subtypes, when transplanted into NOD/SCID mice, contained the leukemia-initiating cells, the resulting disease was similar to that observed in the donor patient (Wang et al., 1998) . These results indicate that the initially transformed cell was a primitive stem cell that took the wrong developmental pathway, presumably depending upon the mutation that occurred. All of these data point to a transformed stem cell source of leukemia.
The 'two-hit' model of leukemogenesis
An important corollary to this discussion of a stem cell origin of AML is the theory that cancer, in general, results from a series of genetic changes that, over time, confer unique properties to a cell that lead to a progression from normalcy to malignancy (Hanahan and Weinberg, 2000) . These genetic alterations include but are not limited to independence in growth factor signaling, escape from apoptosis, and endless ability to replicate. Likewise, AML progression is theorized to result from a stepwise accumulation of genetic mutations. This buildup of mutations takes place over the lifespan of an individual, which is why AML is more than three times as likely to occur in someone aged 65 years versus an individual who is 35 years old (NCI, 2000) . Indeed, the median age at diagnosis of patients with AML is 65 years (Lowenberg et al., 1999) . Given that the origin of AML is a hematopoietic stem cell that has undergone oncogenic mutations, it is reasonable to propose that an aging stem cell is a likely target for this leukemic transformation.
Acute myeloid leukemias are composed of leukemic cells that not only have proliferation and/or survival advantages over other cells of the hematopoietic system but also have diminished/poor differentiation as compared to normal cells (Deguchi and Gilliland, 2002) . In contrast to solid tumors that typically contain point mutations, gene amplifications and/or deletions, (Liu et al., 1993; Romana et al., 1995) , MLL gene rearrangements (Thirman et al., 1993) , Hox family members (Nakamura et al., 1996; Raza-Egilmez et al., 1998) , and the coactivators CBP and p300 (Giles et al., 1997; Rowley et al., 1997) . Specifically, the following chromosomal translocations involving transcriptional elements have been detected in and cloned from human AML samples: CBFb/MYH11 (Claxton et al., 1994) , MLL/CBP (Taki et al., 1997) , MLL/ENL (Thirman et al., 1994) , Nup98/HoxA9 (Borrow et al., 1996) , Nup98/HoxD13 (Pineault et al., 2003) , and, frequently, AML1/ETO (Golub et al., 1994) . Significantly, when these oncogenic translocations are expressed in murine bone marrow experimental models, a myeloid leukemia is usually not evident for 6-12 months (Dash et al., 2002) . In these models of leukemia, this is taken as evidence to support the requirement of additional mutations to cause full acute leukemic disease. The current 'two-hit' model of AML cites mutation in a cellular kinase that results in a constant growthpromoting signal, and mutation in a hematopoietic transcription factor that leads to disrupted developmental potential as the important elements driving leukemogenesis (Dash and Gilliland, 2001; Deguchi and Gilliland, 2002) . Clinically, support for the acquisition of cooperating mutations in the development of AML is well documented. In nearly all cases of chronic myeloid leukemia (CML), a translocation exists that constitutively activates a tyrosine kinase. Common translocations associated with CML include BCR/ ABL, TEL/ABL, TEL/PDGFbR, and TEL/JAK2 (Deguchi and Gilliland, 2002) . Expression of these constitutively active kinases results in increased proliferation and/or survival of affected cells without a block in cellular differentiation. It is the subsequent gain of mutations involving transcription factors that provide the differentiation block and cause the onset of acute disease. Examples of CML progression to AML (or CML blast crisis) provide supporting evidence for this hypothesis. Cases of CML patients with BCR/ABL positive disease (activated kinase) progressing to acute leukemia with ensuing acquisition of either the Nup98/ HoxA9 or AML1/ETO translocations (transcription factors) are documented (Golub et al., 1994; Yamamoto et al., 2000) . To further illustrate this point, the 8;21 chromosomal translocation, which encodes the AML1/ ETO fusion protein, is a recurring genetic abnormality in AML that alters gene expression. This fusion gene is detectable in the stem cells of AML patients, but interestingly, it also remains detectable in stem cells from patients in long-term remission (Miyamoto et al., 2000) . This indicates that other genetic events, besides the AML1/ETO translocation, are necessary for progression and lethality of leukemia. Finally, and probably most compelling, are data obtained in a study of twins who developed AML due to the TEL/AML1 translocation. Upon analysis of this unique biological phenomenon, it was determined that one TEL/AML1 clone was transmitted between the twins in utero. Despite this shared, identical mutation, neither twin was born with leukemic disease. In fact, both twins developed AML later in life but at greatly differing times (Ford et al., 1998; Wiemels et al., 1999a, b) . All these data point to the need for multiple cooperating mutations during leukemogenesis.
It should be noted, however, that translocations involving tyrosine kinases are rare in acute leukemias. While the BCR/ABL fusion is responsible for the majority of cases of CML, similar fusions of activated kinases are not usually found in AMLs. How then is a signal for increased growth and/or survival mediated in these cells? It has recently been observed that point mutations in certain tyrosine kinases can cause constitutive activation of these growth regulators. In particular, Flt3 tyrosine kinase internal tandem duplications (ITD) and activating mutations are widely seen; in fact, Flt3 activation is described as the most common alteration in AML (Mizuki et al., 2000; Tse et al., 2000) . In addition, up to 5% of all cases of AML contain mutations that cause constitutive activation of the kinase c-Kit (Care et al., 2003) . So, the presence of one of these active kinases in addition to the commonly seen transcription factor translocations corresponds well with the two-hit theory of leukemogenesis.
Aging as the second event in leukemia progression
The large amount of work summarized in this review corresponds strongly with a model of multistep leukemogenesis, in which the main culprits of disease consist of an altered transcription factor that causes a differentiation block, and of an activated kinase that can provide limitless growth and survival signals. The combination of these events is critical to disease development. However, as evidenced by the increase in leukemia incidence with advancing age, and the long latency of AML development in mouse models, these detrimental mutations obviously take place over a long period of time. Aging, therefore, must also be a key player in this scenario. Since stem cells have been shown to be the source of AML, and due to the effects of aging on the stem cell population of an individual, we favor a model of AML in which aging may be considered a secondary age-related event in leukemogenesis (Figure 1) . However, the models in Figure 1a and b are not necessarily mutually exclusive. For the sake of simplicity, models a and b are shown as separate events. But secondary mutations (a) that help drive leukemogenesis may be direct results of the age-related changes brought about by increasing age (b). Effects on DNA repair mechanisms and repeated exposure to environmental insults, both internal and external, may cause enough genomic instability to permit the formation, and escape from detection, of the translocations and point
The importance of stem cells in aging and leukemia development D R Bell and G Van Zant mutations/duplications commonly seen in human AMLs. In this regard, aging would provide and promote conditions permissive to leukemic transfomation. Aging stem cells also display decreased developmental potential, which could be similar to the effects of a mutated transcription factor and skew the differentiation of progeny. Furthermore, decreased monitoring by the immune system, another issue in older individuals, may allow disease to progress more efficiently and aggressively. Hence, age may be just as important a factor in AML development as the altered genes themselves.
Final thoughts
It is the purpose of the authors in this review to provide evidence supporting the models of both aging and leukemic transformation of stem cells, and further to demonstrate how these models are related. The identification of malignant stem cells in cancers other than the hematopoietic system, such as breast and brain, provides increasing evidence consistent with a general model of stem cell origin of disease.
It is not surprising that age is the single most important prognosticator of developing cancer. To the extent that at least some, and perhaps many malignancies are stem cell-derived, cancer may provide some of the strongest evidence supporting the concept of stem cell aging. However, the notion that stem cells show age-related decrements in function remains controversial (Iscove and Nawa, 1997) . Readers are directed to recent reviews expanding on the issues surrounding stem cell aging and their potential effects on malignant transformation (DePinho, 2000; Geiger and Van Zant, 2002; Liang and Van Zant, 2003; Van Zant, 2003; Van Zant and Liang, 2003) . The authors' laboratory has used a forward genetic approach in mice to identify quantitative trait loci that regulate a number of stem cell properties, including their numbers, self-renewal, and aging patterns. Two early observations led us to undertake this effort. First, wide variation was observed among inbred mouse strains with respect to key parameters of early hematopoietic cells (Van Zant et al., 1983) . Second, embryo-aggregated cellular chimeras (allophenic mice), composed of cells of two strains, showed wide variation in hematopoietic phenotypes, and shed light on several issues (Van Zant et al., 1990) . Stem cells of the short-lived DBA/2 strain ceased hematopoiesis in the chimeras at a time commensurate with their mean lifespans. Thereafter, hematopoietic cells became wholly derived from the longer-lived C57BL/6 strain. These results demonstrated in a convincing manner that stem cells age differentially. Since the two stem cell populations coexisted throughout embryogenesis and adult life in precisely the same bone marrow milieu, the differential aging had to be regulated by cell-intrinsic (genetic) mechanisms rather than extrinsic, environmental differences. Armed with this knowledge and the growing realization of the extensive natural variation between mouse strains, we and others have made use of such interstrain differences in experiments to identify the underlying responsible genes (Muller-Sieburg and Riblet, 1996; Chen et al., 2000a, b; Van Zant, 1997, 1999a, b; Geiger et al., 2001 Geiger et al., , 2004 Morrison et al., 2002) . These are works in progress and point upto the difficulties in unraveling complex quantitative traits relevant to hematopoiesis (Biola et al., 2003) . However, recent genetic advances such as microarrays, complete genome sequences of several mouse strains, including the C57BL/6 and DBA/2 strains, and more advanced bioinformatics tools have led to significant progress in the last few years. An important issue for the future is to relate the genes important for stem cell phenotypes, aging, and malignant transformation. There is obviously wide natural variation in the latency of carcinogenesis and progression of the disease in different individuals and mouse strains, even in the latter when cancer is experimentally induced by the same genetic translocation. The search for, and manipulation of, the underlying modifier genes represent an important but largely untapped approach to cancer therapy. Until now, the genetic complexity of sifting through the genome in search of modifiers, let alone understanding the molecular pathways by which they wielded their influence, was difficult, if not impossible. The genetic tools for such experimental studies are now in place and are being used in this effort and it is predicted that significant advances are forthcoming in the near future.
